直覺手術 (ISRG) 2012 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Ladies and gentlemen, thank you for standing by. Welcome to the Intuitive Surgical First Quarter Earnings Release Call. At this time all participants are in a listen-only mode. Later we will conduct a question and answer session. (Operator Instructions). I would now like to turn the conference over to our host, Mr. Calvin Darling, Senior Director of Finance for Intuitive Surgical. Please go ahead.

    各位女士、先生,感謝您稍候。歡迎參加直覺外科第一季財報發布電話會議。目前所有與會者皆處於僅收聽模式。稍後我們將進行問答環節。(接線員指示)現在我想將會議交給我們的主持人——直覺外科財務資深總監 Calvin Darling 先生。請開始。

  • Calvin Darling - Senior Director of Finance

    Calvin Darling - Senior Director of Finance

  • Thank you, good afternoon and welcome to Intuitive Surgical's first-quarter conference call. With me today we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Aleks Cukic, our Vice President of Strategic Planning.

    謝謝,下午好,歡迎參加直覺外科第一季電話會議。今天與我一同出席的有:我們的總裁暨執行長 Gary Guthart、財務長 Marshall Mohr,以及策略規劃副總裁 Aleks Cukic。

  • Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the Company's Securities and Exchange Commission filings. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.

    在開始之前,我想提醒各位,今天電話會議中提及的評論可能被視為包含前瞻性陳述。由於某些風險與不確定性,實際結果可能與明示或暗示的內容有重大差異。這些風險與不確定性已在本公司向美國證券交易委員會(SEC)提交的文件中詳加說明。提醒潛在投資人勿過度依賴此類前瞻性陳述。

  • Please note that this conference call will be available for audio replay on our website at IntuitiveSurgical.com on the audio archive section under our investor relations page. In addition, today's press release has been posted to our website.

    請注意,本次電話會議將可於我們網站 IntuitiveSurgical.com 的投資人關係頁面下之音訊存檔區提供錄音重播。此外,今天的新聞稿也已發布於我們的網站。

  • Today's format will consist of providing you with highlights of our first quarter's results, as described in our press release announced earlier today, followed by a question and answer session.

    今天的流程將先提供第一季業績重點(如同我們稍早發布的新聞稿所述),接著進行問答環節。

  • Gary will present the quarter's business and operational highlights, Marshall will provide a review of our first-quarter financial results, Aleks will discuss marketing and clinical highlights, then I'll provide an update to our financial forecast for 2012. And finally, we will host a question-and-answer session.

    Gary 將說明本季的業務與營運重點;Marshall 將回顧第一季財務結果;Aleks 將分享行銷與臨床重點;接著我將更新我們對 2012 年的財務預測。最後,我們將進行問答環節。

  • With that, I will turn it over to Gary.

    那麼,我把時間交給 Gary。

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Thank you for joining us today. In this first quarter our team has executed well and we have experienced strong performance in procedures, encouraging acceptance of our new products and the financial results that follow.

    感謝各位今天加入我們。本第一季,我們的團隊執行表現良好,手術量表現強勁,新產品的接受度令人鼓舞,並帶動隨後的財務成果。

  • For 2012, Intuitive is focused on the following. First, continuing our growth in gynecology and urology worldwide through outstanding execution in the field. Second, disciplined execution of our Single-Site and vessel sealing launches, focused on outstanding early customer experiences. Third, building robust clinical programs with leading customers in emerging procedures and general surgery, thoracic surgery and trans-oral surgery, and finally, strengthening our capabilities in international markets, particularly Europe, Japan and Korea.

    在 2012 年,直覺外科聚焦於以下幾點。第一,透過前線的卓越執行,持續推動全球婦科與泌尿科的成長。第二,以紀律性執行 Single-Site 與血管封合產品的上市推廣,並聚焦於打造早期客戶的卓越使用體驗。第三,與領先客戶共同建立強健的臨床計畫,涵蓋新興手術與一般外科、胸腔外科及經口手術。最後,強化我們在國際市場的能力,特別是歐洲、日本與韓國。

  • With regard to procedures, we experienced strong growth in general surgery and gynecology, leading to year-over-year procedure growth of approximately 29%. With uptake in colorectal procedures and the introduction of Single-Site in the United States, the category of general surgery grew at the highest rate this quarter. Worldwide urology procedures grew year-over-year as well, led by growth in European dVP, while US urology was flat. Aleks will provide additional procedure commentary later in the call.

    就手術量而言,我們在一般外科與婦科皆呈現強勁成長,使得手術量年增約 29%。在大腸直腸手術的採用增加以及美國導入 Single-Site 的帶動下,一般外科本季成長率最高。全球泌尿科手術量亦呈年增,主要由歐洲 dVP 的成長帶動,而美國泌尿科則持平。Aleks 稍後將在會議中提供更多手術量相關評論。

  • As we have mentioned on previous calls, we have been investing in improving our structural capabilities in Japan. Our team has worked with Japan's MHLW on reimbursement for da Vinci prostatectomy, receiving reimbursement approval on April 1.

    如同我們在先前電話會議中提到的,我們一直在投資以提升在日本的組織能力。我們的團隊已與日本厚生勞動省(MHLW)就達文西前列腺切除術的健保給付進行合作,並於 4 月 1 日取得給付核准。

  • Intuitive Surgical Japan has also successfully transitioned the import license for da Vinci S from Johnson & Johnson Japan to Intuitive Surgical Japan this month. We are encouraged by our progress in Japan and we will continue to invest to clear the path for increased da Vinci use.

    本月,直覺外科日本公司也已成功將達文西 S 的進口許可,從嬌生日本(Johnson & Johnson Japan)移轉至直覺外科日本公司。我們對在日本的進展感到鼓舞,並將持續投資,以清除障礙、為達文西使用量提升鋪路。

  • Overall, international system sales were encouraging. However, our first-quarter system sales in Europe are somewhat disappointing. This is likely a combination of both economic pressures in Europe as well as organizational capability.

    整體而言,國際系統銷售令人鼓舞。然而,我們第一季在歐洲的系統銷售略令人失望。這可能同時反映歐洲的經濟壓力以及組織能力等因素的綜合影響。

  • Turning to operational highlights for the first quarter, procedures grew 29% over the first quarter of 2011. We sold 140 da Vinci Surgical Systems, up from 120 during the first quarter of last year. Total revenue was $495 million, up 28% over last year.

    轉到第一季的營運重點,手術量較 2011 年第一季成長 29%。我們售出 140 套達文西手術系統,高於去年第一季的 120 套。總營收為 4.95 億美元,較去年成長 28%。

  • Instrument and accessory revenue increased to $208 million, up 32% over Q1 of 2011. Total recurring revenue grew to $289 million, up 31% from prior year and comprising 58% of total revenue.

    器械與配件營收增加至 2.08 億美元,較 2011 年第一季成長 32%。總經常性營收成長至 2.89 億美元,較去年同期成長 31%,占總營收的 58%。

  • Net income was $144 million, up 38% over last year. We generated an operating profit of $228 million before non-cash stock option expense, up 26% from the first quarter of last year and representing 46% of Q1 revenue.

    淨利為 1.44 億美元,較去年成長 38%。在扣除非現金的股票選擇權費用前,我們的營業利益為 2.28 億美元,較去年第一季成長 26%,相當於第一季營收的 46%。

  • We ended the quarter with $2.371 billion in cash and investments, up $199 million from last quarter. Significant cash outlays during the quarter included $50 million invested in the acquisition of our Korean distributor, fixed assets and intellectual property. Excluding the impact of these outlays, as well as $83 million from stock proceeds and $30 million used for working capital, we generated $211 million in gross cash flow from operations, which is 147% of our reported GAAP net income in the first quarter.

    本季結束時,我們的現金與投資為 23.71 億美元,較上季增加 1.99 億美元。本季重大現金支出包括:投入 5,000 萬美元用於收購我們的韓國經銷商、固定資產與智慧財產權。若排除這些支出影響,以及 8,300 萬美元的股票發行收入與 3,000 萬美元的營運資金使用,我們由營運產生的毛現金流為 2.11 億美元,為第一季依 GAAP 報告之淨利的 147%。

  • The first quarter has been an active one for our product development, marketing and operations teams. In the quarter, we completed our first phase of rollout for Single-Site instruments and accessories for da Vinci SI in the United States.

    第一季對我們的產品開發、行銷與營運團隊而言相當活躍。本季我們完成了在美國針對達文西 SI 的 Single-Site 器械與配件第一階段推廣。

  • Recall Single-Site is a platform for increasing patient value by reducing the number of incisions required by traditional multiport minimally invasive surgery. Instead of the multiple incisions of traditional laparoscopy, the body is entered through a single incision at the umbilicus.

    回顧一下,Single-Site 是一個平台,透過減少傳統多孔微創手術所需的切口數來提升病患價值。相較於傳統腹腔鏡的多個切口,Single-Site 透過肚臍處的單一切口進入體內。

  • Currently, Single-Site is cleared for single-incision cholecystectomy in the US and for broader educations indications in Europe. Experiences by our Single-Site customers in the US indicate that cholecystectomy procedure is safe, repeatable and teachable. Market response to date has been very encouraging.

    目前,Single-Site 在美國已獲准用於單切口膽囊切除術,在歐洲則獲准用於更廣泛的教育用途適應症。我們在美國的 Single-Site 客戶經驗顯示,膽囊切除術是安全、可重複且可教學的。迄今市場反應非常令人鼓舞。

  • We are working with our customers in Europe to identify procedures in which Single-Site can bring additional patient value beyond cholecystectomy.

    我們正與歐洲客戶合作,找出除膽囊切除術之外,Single-Site 還能帶來額外病患價值的手術項目。

  • We continue to focus on developing products that enable surgeons to convert traditionally open surgeries to minimally invasive surgery using da Vinci. In the quarter we completed our first customer access work on our EndoWrist vessel sealer, and are pleased with its performance in surgery.

    我們持續專注於開發產品,使外科醫師能使用達文西將傳統開放式手術轉為微創手術。本季我們完成了 EndoWrist 血管封合器的首批客戶使用作業,並對其在手術中的表現感到滿意。

  • Our vessel sealer brings to da Vinci surgeries surgeons full articulation and precise control. We think this instrument will facilitate robotic general surgery.

    我們的血管封合器為達文西手術帶來完整的關節活動度與精準控制。我們認為這項器械將促進機器人一般外科手術的發展。

  • We are communicating with the FDA regarding our da Vinci stapler, and we're making progress in answer answering their questions.

    我們正就達文西縫合切割器(stapler)與 FDA 進行溝通,並在回覆其問題方面持續取得進展。

  • In imaging our Firefly Fluorescence Imaging System is now being used regularly to image kidney vasculature during da Vinci partial nephrectomy. Surgeons are also exploring the use of Firefly in visualizing blood flow in da Vinci colorectal procedures.

    在影像方面,我們的 Firefly 螢光影像系統目前已被常態性用於達文西部分腎切除術中腎臟血管的成像。外科醫師也在探索於達文西大腸直腸手術中使用 Firefly 來觀察血流。

  • As we enter new markets and drive into new product arenas, we continue to invest in building our team and expanding partnerships, and in acquiring those technologies that can make a difference to robotic surgery.

    隨著我們進入新市場並拓展至新產品領域,我們持續投資於團隊建置、擴大合作夥伴關係,並收購能對機器人手術帶來差異化的技術。

  • This quarter we added 94 people to our team, predominantly in sales, manufacturing and R&D, bringing our total team to 2018 employees. I will now pass the time over to Marshall, our Chief Financial Officer.

    本季我們新增 94 位同仁,主要在銷售、製造與研發部門,使員工總數達到 2,018 人。現在我把時間交給我們的財務長 Marshall。

  • Marshall Mohr - CFO

    Marshall Mohr - CFO

  • Thank you, Gary. Our first-quarter revenue was $495 million, up 28% compared with $388 million for the first quarter of 2011, and $2 million less than the $497 million reported for the fourth quarter of 2011.

    謝謝你,Gary。我們第一季營收為 4.95 億美元,較 2011 年第一季的 3.88 億美元成長 28%,並較 2011 年第四季報告的 4.97 億美元少 200 萬美元。

  • First-quarter revenues by product category were as follows. First-quarter instrument and accessory revenue was $208 million, up 32% compared with $157 million for the first quarter of 2011, and up 6% compared with $196 million in the fourth quarter of 2011.

    第一季按產品類別的營收如下。第一季器械與配件營收為 2.08 億美元,較 2011 年第一季的 1.57 億美元成長 32%,並較 2011 年第四季的 1.96 億美元成長 6%。

  • Year-over-year instrument and accessory growth was driven by procedure growth of 29% and initial purchases of recently launched products, including Single-Site starter kits and our Firefly product.

    器械與配件的年增成長主要由 29% 的手術量成長,以及近期上市產品的初期採購所帶動,其中包括 Single-Site 入門套件與我們的 Firefly 產品。

  • Note that the first quarter of 2012 included one more surgical day than the first quarter of 2011 due to leap year.

    請注意,由於閏年因素,2012 年第一季比 2011 年第一季多了一個手術日。

  • Instrument and accessory growth relative to the first quarter of 2011 was primarily driven by procedure growth in sales for our Single-Site starter kits, partially offset by lower first-quarter stocking orders associated with seasonally lower first-quarter system sales.

    相較於 2011 年第一季,器械與配件的成長主要由我們 Single-Site 入門套件銷售的手術量成長所帶動,但部分被第一季因系統銷售季節性較低而導致的較低備貨訂單所抵銷。

  • Instrument and accessory revenue realized per procedure, including initial stocking orders of $1985 per procedure was higher than the first quarter of 2011 by $50, and $10 higher than the fourth quarter of 2011.

    每例手術所實現的器械與配件收入(包含每例手術 1,985 美元的初始備貨訂單)較 2011 年第一季高出 50 美元,且較 2011 年第四季高出 10 美元。

  • Over time we expect instruments and accessories per procedure to decline slowly, given the initial stocking orders have a lower impact on a larger install base. This natural decline has been more than offset in recent quarters by the positive impact of our new instrument and accessory products, specifically Single-Site, Firefly, and thoracic lung kit. Instrument and accessory revenue per procedure will fluctuate based on the rate of adoption of newer products as well as product and procedure mix.

    隨著時間推移,我們預期每例手術的器械與配件用量將緩慢下降,因為在更大的裝機基礎下,初始備貨訂單的影響會降低。近幾季此一自然下降已被我們新器械與配件產品的正面影響所大幅抵銷,特別是 Single-Site、Firefly 與胸腔肺部套件。每例手術的器械與配件收入將隨新產品採用速度以及產品與手術組合而波動。

  • First-quarter 2012 systems revenue of $207 million increased 24% compared with $167 million of systems revenue for the first quarter of 2011, and decreased 8% compared with $225 million of systems revenue for the fourth quarter of 2011.

    2012 年第一季系統收入為 2.07 億美元,較 2011 年第一季的 1.67 億美元增加 24%,較 2011 年第四季的 2.25 億美元減少 8%。

  • We sold 140 systems in the fourth quarter(Sic-see press release) of 2012 compared with 120 systems in the first quarter 2011 and 152 systems in the fourth quarter of 2011. The first quarter of 2011 system count included systems involving trade-ins of older units comprised of 19 standard systems and 27 da Vinci S's. The first quarter of 2011 system count included 13 standard trade-ins and 19 da Vinci S trade-ins, while the fourth quarter of 2011 included 23 standard trade-ins and 27 da Vinci S trade-ins.

    2012 年第四季(原文如此—請參見新聞稿)我們售出 140 套系統,相較之下 2011 年第一季為 120 套、2011 年第四季為 152 套。2011 年第一季的系統數量包含以舊機換購的系統,其中包括 19 套標準系統與 27 套 da Vinci S。2011 年第一季的系統數量包含 13 套標準換購與 19 套 da Vinci S 換購,而 2011 年第四季包含 23 套標準換購與 27 套 da Vinci S 換購。

  • Our first quarter average selling price per system, including all da Vinci models, was $1.47 million, an increase from the $1.38 million realized in the fourth quarter of 2011 and the same as the fourth quarter. ASPs include simulators and systems configured with Firefly, but exclude upgrades. The increase in average sales price relative to the first-quarter of 2011 reflects a higher proportion of dual consoles, a higher number of systems shipped with surgical simulators and Firefly, partially offset by an increased proportion of trade-in.

    我們第一季每套系統的平均售價(包含所有 da Vinci 機型)為 147 萬美元,較 2011 年第四季實現的 138 萬美元增加,且與第四季相同。ASP 包含模擬器及配置 Firefly 的系統,但不包含升級。相較於 2011 年第一季,平均售價上升反映雙控制台占比提高、搭配手術模擬器與 Firefly 出貨的系統數量增加,但部分被換購占比提高所抵銷。

  • We sold 25 dual console systems in the first quarter of 2012 compared to 16 in the first quarter of 2011 and 29 in the fourth quarter of 2011. ASP's will fluctuate quarter to quarter based on product, customer, and trade index as well as foreign exchange rates on direct sales to foreign customers.

    2012 年第一季我們售出 25 套雙控制台系統,相較之下 2011 年第一季為 16 套、2011 年第四季為 29 套。ASP 將因產品、客戶與換購指數,以及對海外客戶直接銷售的外匯匯率而在各季間波動。

  • Service revenue of $81 million increased 27% compared with $64 million last year, and increased 7% compared with $75 million last quarter. The growth in service revenue was primarily driven by a larger system installed base.

    服務收入為 8,100 萬美元,較去年同期的 6,400 萬美元增加 27%,較上季的 7,500 萬美元增加 7%。服務收入成長主要由更大的系統裝機基礎所帶動。

  • Total first-quarter recurring revenue comprised of instrument, accessory and service revenue of $289 million increased 31% compared with the first quarter of 2011, and increased 6% compared with the fourth quarter of 2011. Recurring revenue represented 58% of total first-quarter revenue compared with 57% in the first quarter last year and 55% last quarter.

    第一季經常性收入總額(由器械、配件與服務收入構成)為 2.89 億美元,較 2011 年第一季增加 31%,較 2011 年第四季增加 6%。經常性收入占第一季總收入的 58%,相較之下去年第一季為 57%,上季為 55%。

  • International results were as follows. Procedures outside of the US grew approximately 31% on a year-to-year basis, led by growth in Europe particularly the dVP. We also experienced growth in our other targeted procedures, including dVH in Europe.

    國際業績如下:美國以外的手術量年增約 31%,成長主要由歐洲帶動,尤其是 dVP。我們在其他目標手術上也出現成長,包括歐洲的 dVH。

  • First-quarter revenue outside of the US at $105 million increased 15%, compared with revenue of $91 million in the first quarter of 2011, and decreased 2% compared with seasonally strong fourth quarter revenue of $107 million.

    美國以外第一季收入為 1.05 億美元,較 2011 年第一季的 9,100 萬美元增加 15%,較季節性強勁的第四季收入 1.07 億美元減少 2%。

  • Instrument and accessory revenue outside of the US grew 24% year-over-year and 22% sequentially.

    美國以外的器械與配件收入年增 24%,且較前一季增加 22%。

  • We sold 35 systems outside of the US, compared with 31 in the first quarter of 2011 and 39 last quarter. We sold 14 systems in Europe in the first quarter, compared with 15 in the first quarter of 2011 and 23 in the fourth quarter of 2011.

    我們在美國以外售出 35 套系統,相較之下 2011 年第一季為 31 套、上季為 39 套。我們第一季在歐洲售出 14 套系統,相較之下 2011 年第一季為 15 套、2011 年第四季為 23 套。

  • European system sales reflect the challenging economic environment. However, we're also taking steps to improve our execution.

    歐洲系統銷售反映了具挑戰性的經濟環境。然而,我們也正在採取措施以改善執行。

  • Capital sales in rest of world markets increased to 21 systems in the first quarter, compared to 16 in each of the first and fourth quarters of 2011. Aleks will provide additional details of overseas system sales.

    在世界其他市場,第一季資本銷售增加至 21 套,相較之下 2011 年第一季與第四季各為 16 套。Aleks 將提供海外系統銷售的更多細節。

  • Moving on to the remainder of the P&L, gross margin in the first-quarter of 72% was the same as the first quarter of 2011 and lower than the 73% last quarter. The lower gross margin compared to the fourth quarter primarily reflected lower margins on our newly introduced products.

    接著看損益表其餘項目,第一季毛利率為 72%,與 2011 年第一季相同,且低於上季的 73%。相較於第四季,毛利率較低主要反映我們新推出產品的毛利較低。

  • Margins on newly launched products like Single-Site will typically be lower than our mature products, reflecting vendor pricing on low volume, temporary tooling costs and other startup costs. However, over time, as volumes increase we refine the manufacturing process in the product, we would expect to see improvement in the margins of these newer products.

    像 Single-Site 這類新上市產品的毛利通常會低於我們的成熟產品,原因包括低量下的供應商定價、暫時性治具成本及其他啟動成本。然而,隨著時間推移,當出貨量增加且我們在產品中精進製造流程時,我們預期這些較新產品的毛利將有所改善。

  • First-quarter 2012 operating expenses of $163 million were 25% compared -- up 25% compared with the first quarter of 2011, and were approximately the same as those for the fourth quarter of 2011. Relative to the fourth-quarter operating expenses, the first-quarter expenses included costs associated with employees added during the quarter and payroll taxes on a higher level of employee stock option exercises, offset by lower engineering project costs which fluctuate with prototype spending.

    2012 年第一季營業費用為 1.63 億美元,較 2011 年第一季增加 25%,且與 2011 年第四季大致相同。相較於第四季營業費用,第一季費用包含本季新增員工相關成本,以及因員工股票選擇權行使水準較高而產生的薪資稅;但部分被工程專案成本較低所抵銷,該成本會隨原型支出而波動。

  • We added 94 employees in the quarter, including 41 employees in commercial operations and 44 employees in product operations.

    本季我們新增 94 名員工,其中商業營運新增 41 名、產品營運新增 44 名。

  • First-quarter 2012 operating income was $193 million or 39% of sales compared with $148 million or 38% of sales for the first quarter of 2011, and $200 million or 40% of sales for the fourth quarter of 2011.

    2012 年第一季營業利益為 1.93 億美元,占銷售額 39%;相較之下 2011 年第一季為 1.48 億美元,占銷售額 38%,2011 年第四季為 2.00 億美元,占銷售額 40%。

  • First-quarter 2012 operating income reflected $34 million of non-cash stock compensation expense compared with $32 million for the first quarter of 2011 and $35 million last quarter. We have changed our annual stock option grant process such that one-half of the employees' annual grants were issued in February 15 and the other half will be issued on August 15. The first-quarter impact of the February 15 grant was more than offset by the full vesting of options granted in 2008.

    2012 年第一季營業利益包含 3,400 萬美元的非現金股票薪酬費用,相較之下 2011 年第一季為 3,200 萬美元、上季為 3,500 萬美元。我們已調整年度股票選擇權授予流程,使員工年度授予的一半於 2 月 15 日發放,另一半將於 8 月 15 日發放。第一季 2 月 15 日授予的影響,已被 2008 年授予之選擇權全數歸屬所帶來的影響所抵銷且有餘。

  • We would expect non-cash compensation expense to increase in the second quarter, reflecting the full quarter impact of the February 15 grant, and to increase further in the third quarter with the August 15 grant.

    我們預期第二季非現金薪酬費用將增加,反映 2 月 15 日授予的整季影響;並且在第三季隨 8 月 15 日授予而進一步增加。

  • Our effective tax rate for the first quarter of 27% was lower than our rate for 2011 of 30%. The decrease reflects a one-time benefit associated with a change in the way the IRS interprets the rules associated with Section 199 domestic manufacturing tax credit.

    第一季有效稅率為 27%,低於我們 2011 年的 30%。此下降反映一次性利益,與美國國稅局(IRS)對第 199 條國內製造稅額抵免相關規則之解釋方式變更有關。

  • We expect the rate for the remainder of the year to be approximately 31%. The increase relative to 2011 reflects no research and development credit, a lower mix of foreign earnings, partially offset by ongoing Section 199 tax credit.

    我們預期今年剩餘期間的稅率約為 31%。相較於 2011 年的上升,反映未有研發抵免、海外獲利占比較低;但部分被持續的第 199 條稅額抵免所抵銷。

  • Our net income was $144 million or $3.50 per share, compared with $104 million or $2.59 per share for the first quarter of 2011, and $151 million or $3.75 per share for the fourth quarter of 2011.

    我們的淨利為 1.44 億美元或每股 3.50 美元,相較之下 2011 年第一季為 1.04 億美元或每股 2.59 美元,2011 年第四季為 1.51 億美元或每股 3.75 美元。

  • Now moving to the balance sheet. We ended the first quarter with cash and investments of $2.4 billion, up $199 million compared with December 31, 2011. The increase reflects $167 million of cash flow from operations, $83 million from the exercise of stock options, partially offset by $50 million associated with the purchase of our Korean distributor, purchase of capital, and IP.

    接著看資產負債表。我們第一季期末現金與投資為 24 億美元,較 2011 年 12 月 31 日增加 1.99 億美元。此增加反映營運現金流入 1.67 億美元,以及股票選擇權行使帶來的 8,300 萬美元,部分被約 5,000 萬美元所抵銷,該金額與收購我們的韓國經銷商、資本支出及智慧財產權(IP)購置相關。

  • During the fourth quarter we did not repurchase any of our common stock. However, we retained the option to exercise the remaining Board-authorized buybacks of $568 million.

    在第四季期間,我們未回購任何普通股。然而,我們仍保留行使董事會已核准之剩餘回購額度(5.68 億美元)的選擇權。

  • Our accounts receivable balance increased to $300 million at March 31 from $298 million at December 31. Our net inventory increased $119 million at March 31 from $112 million at December 31.

    我們的應收帳款餘額於 3 月 31 日增至 3.00 億美元,高於 12 月 31 日的 2.98 億美元。我們的淨存貨於 3 月 31 日為 1.19 億美元,高於 12 月 31 日的 1.12 億美元。

  • And with that I would like to turn it over to Aleks, who will go over our sales, marketing and clinical highlights.

    接下來我想把時間交給 Aleks,由他說明我們在銷售、行銷與臨床方面的重點。

  • Aleks Cukic - VP of Strategic Planning

    Aleks Cukic - VP of Strategic Planning

  • Thank you, Marshall. During the first quarter we sold 140 da Vinci systems -- 105 in United States, 14 into Europe and 21 into rest of world markets. As part of the 140 systems sales, 19 standard da Vinci systems and 27 da Vinci S systems were traded in for credit against sales for new da Vinci Si systems.

    謝謝你,Marshall。第一季我們共售出 140 台達文西(da Vinci)系統——其中 105 台在美國、14 台在歐洲、21 台在世界其他市場。在這 140 台系統銷售中,有 19 台標準 da Vinci 系統與 27 台 da Vinci S 系統以折抵方式換購新的 da Vinci Si 系統。

  • We had a net 94 system additions to the installed base during the quarter, which brings to 2226 the cumulative number of da Vinci systems worldwide -- 1615 in the United States, 379 in Europe and 232 in rest of world markets. 80 of the 140 systems installed during the quarter represented repeat system sales to existing customers.

    本季我們的裝機基數淨增加 94 台,使全球累計 da Vinci 系統數量達到 2,226 台——其中美國 1,615 台、歐洲 379 台、世界其他市場 232 台。本季安裝的 140 台系統中,有 80 台屬於既有客戶的重複購買。

  • In total, 132 of the 140 systems sold represented da Vinci Si systems, which included 25 dual console systems. The 35 system sales internationally included 7 into Japan, 4 into India and 3 into the countries of Italy, the UK and Australia. While our overall international system sales were strong, our Q1 EU system sales were somewhat disappointing and below historical trends.

    總計而言,售出的 140 台系統中有 132 台為 da Vinci Si 系統,其中包含 25 台雙控制台系統。國際市場的 35 台系統銷售包括:日本 7 台、印度 4 台,以及義大利、英國與澳洲各 3 台。雖然我們整體國際系統銷售表現強勁,但第一季歐盟(EU)系統銷售略顯令人失望,低於歷史趨勢。

  • Clinically we had a strong quarter, achieving an overall year-over-year procedure growth rate of approximately 29%. Gynecology, international dVP, along with the emerging categories of general surgery and thoracic surgery accounted for a large part of this growth. Cholecystectomy, colon and rectal resections, lobectomy, dVH and endometriosis resections, myomectomy and partial nephrectomy all exhibited strong year-over-year growth.

    在臨床方面,我們本季表現強勁,整體手術量年增率約 29%。婦科、國際 dVP,以及新興的一般外科與胸腔外科類別,構成了此成長的主要部分。膽囊切除術、結腸與直腸切除、肺葉切除術、dVH 與子宮內膜異位切除、子宮肌瘤切除術,以及部分腎切除術,皆呈現強勁的年增成長。

  • International dVP growth remained strong both in Europe and rest of the world. However, in the US, dVP has felt some recent pressure from nonsurgical disease management -- namely active surveillance. With the international market playing an ever-increasing role in the worldwide procedure numbers, overall worldwide dVP growth remains positive.

    國際 dVP 成長在歐洲與世界其他地區皆維持強勁。然而在美國,dVP 近期受到非手術疾病管理方式——亦即主動監測(active surveillance)——的壓力。隨著國際市場在全球手術量中的占比持續提高,全球整體 dVP 成長仍維持正向。

  • Recent new product launches are all proceeding well. The attachment rate for both the da Vinci Simulator and our Firefly product remained high, which is helping to buoy da Vinci system ASPs. The initial customer response to our da Vinci Single-Site product line has been very positive, with many centers up and running and several more scheduled for training.

    近期的新產品上市進展皆良好。da Vinci 模擬器(Simulator)與我們的 Firefly 產品之搭售率(attachment rate)仍維持在高水準,有助於支撐 da Vinci 系統的平均售價(ASP)。客戶對 da Vinci Single-Site 產品線的初期反應非常正面,許多中心已開始運作,另有數個中心已排定訓練。

  • We initiated a phased rollout of the Vessel Sealer product in the second half of the quarter, and early customers are beginning to perform their initial cases. The product is performing well, and early customer feedback has been positive. But as with all new product launches, customer feedback processes and operational scaling will remain central themes.

    我們在本季後半段啟動了 Vessel Sealer 產品的分階段推廣,早期客戶已開始進行初始案例。產品表現良好,早期客戶回饋亦為正面。但如同所有新產品上市,客戶回饋流程與營運規模化仍將是核心主題。

  • Throughout this period, the focus of our operations team will be to optimize manufacturing while reducing costs. During the quarter, over 350 abstracts and papers representing a variety of surgical specialties were published within various peer-reviewed journals, while the clinical conferences were abundant with live da Vinci procedure transmissions, postgraduate robotic courses, podium presentations and clinical poster sessions.

    在此期間,我們營運團隊的重點將是最佳化製造並降低成本。本季在各類同儕審查期刊中,發表了超過 350 篇摘要與論文,涵蓋多種外科專科;同時臨床會議也相當密集,包含 da Vinci 手術的現場轉播、研究所後機器人課程、口頭報告以及臨床海報發表。

  • As we discussed, da Vinci colon and rectal surgery is an emerging category and is receiving a lot of clinical interest, and for good reason. While clinical experiences for laparoscopic colon and rectal surgery date back to 1991, the adoption has been lagging.

    如我們所討論,da Vinci 結腸與直腸手術屬於新興類別,並受到大量臨床關注,且其來有自。雖然腹腔鏡結腸與直腸手術的臨床經驗可追溯至 1991 年,但其採用率一直落後。

  • In a recent edition of The American Surgeon, Dr. Joseph Carmichael and his colleagues from the University of California Irvine published a comprehensive review on the utilization of laparoscopy in colorectal surgery for cancer in academic medical centers. In it, they segment various colorectal surgical procedures as they relate to laparoscopic adoption.

    在近期一期《The American Surgeon》中,加州大學爾灣分校的 Joseph Carmichael 醫師及其同事發表了一篇全面性回顧,探討學術醫學中心在大腸直腸癌手術中使用腹腔鏡的情況。文中依不同大腸直腸手術類型,區分其腹腔鏡採用情形。

  • University Hospital Consortium, or UHC, is a large organization consisting of 112 academic medical centers and their affiliates, representing approximately 90% of the nation's nonprofit academic medical centers. The study, based off data from the UHC database, included records from 22,780 patients who had undergone open or laparoscopic colon and rectal surgery for cancer between 2007 and 2009.

    University Hospital Consortium(UHC)是一個大型組織,由 112 家學術醫學中心及其附屬機構組成,約代表全國 90% 的非營利學術醫學中心。本研究基於 UHC 資料庫數據,納入 2007 至 2009 年間 22,780 名接受大腸直腸癌開腹或腹腔鏡結腸與直腸手術的病患紀錄。

  • Interestingly, 19,408 or over 85% of these patients received an open surgery as compared to 3372, or 14.8%, who had received a laparoscopic procedure. The study reports that as a percentage, the most commonly performed laparoscopic colon resection was a total colectomy at 22.6%, followed by a sigmoid resection of 17.3%. The least common were abdominoperineal resections at 8%, transverse colon resections at 10%.

    有趣的是,這些病患中有 19,408 人(超過 85%)接受開腹手術,相較之下有 3,372 人(14.8%)接受腹腔鏡手術。研究指出,以比例而言,最常進行的腹腔鏡結腸切除為全結腸切除術(total colectomy),占 22.6%,其次為乙狀結腸切除(sigmoid resection),占 17.3%。最少見的是腹會陰切除術(abdominoperineal resection)占 8%,以及橫結腸切除(transverse colon resection)占 10%。

  • When subcategories were consolidated and analyzed, it was reported that laparoscopic surgery was incorporated in less than 20% of colon cancer resection and less than 10% of rectal cancer resections.

    當將各子類別整併後進行分析,研究報告指出:腹腔鏡手術在結腸癌切除中的採用率低於 20%,在直腸癌切除中的採用率低於 10%。

  • Historically, both patient value and da Vinci's procedure adoption have been strongest where traditional lab and MIS adoption has been limited. This is often the case within procedure categories where MIS is deemed clinically challenging.

    從歷史來看,病患價值與 da Vinci 手術採用率最強的領域,往往出現在傳統開腹與微創手術(MIS)採用受限之處。這通常發生在被認為臨床上具挑戰性的 MIS 手術類別中。

  • While every procedure has its own set of variables, prostatectomy, complex hysterectomy, partial nephrectomy, myomectomy, sacrocolpopexy and lobectomy have shared at least one common bond, which is that each of them, despite years of clinical effort, was limited to a relatively small number of centers, resulting in limited MIS penetration. We believe that MIS colorectal surgery is consistent with this theme.

    雖然每項手術都有其變數,但前列腺切除術、複雜子宮切除術、部分腎切除術、子宮肌瘤切除術、薦骨陰道固定術(sacrocolpopexy)以及肺葉切除術,至少共享一個共同點:即使經過多年臨床努力,這些手術仍僅限於相對少數中心,導致 MIS 滲透率有限。我們認為 MIS 大腸直腸手術也符合此一主題。

  • While laparoscopic colorectal surgery is limited in the US, lab colon initiatives throughout Korean and Japanese universities have been more ambitious, which has led to some academic analysis of da Vinci's role versus laparoscopy.

    雖然美國的腹腔鏡大腸直腸手術仍受限制,但韓國與日本各大學推動的腹腔鏡結腸計畫更為積極,因而促成了一些關於 da Vinci 相較於腹腔鏡角色的學術分析。

  • A comparative study of urinary voiding and sexual function following a total mesorectal excision or TME for rectal cancer was recently published in the annals of Surgical Oncology. The study, authored by Dr. Sang Yoon Kim and his colleagues from Yangtze University, compared laparoscopic and robotic TME as it relates to complications in urinary continence and sexual function, which are both common complications in rectal cancer surgery.

    近期《Surgical Oncology》期刊發表了一項比較研究,探討直腸癌病患在接受全直腸系膜切除術(total mesorectal excision,TME)後的排尿與性功能。該研究由揚子大學的 Sang Yoon Kim 醫師及其同事撰寫,比較腹腔鏡與機器人 TME 在尿失禁與性功能等併發症方面的差異;這兩者皆為直腸癌手術常見併發症。

  • 69 patients who underwent a lap or robotic procedure were prospectively enrolled. Their urogenital function was evaluated by uroflowmetry, standard questionnaires to establish an international prostate symptom score, and international index of erectile function score were given before surgery and at one, three, six and 12 months post-surgery. Their initial findings were not surprising, in that bladder function within both cohorts significantly decreased one month post-surgery.

    共有 69 名接受腹腔鏡或機器人手術的病患以前瞻性方式納入研究。其泌尿生殖功能以尿流速測定(uroflowmetry)評估,並透過標準問卷建立國際前列腺症狀評分(international prostate symptom score),以及於術前與術後 1、3、6、12 個月施測國際勃起功能指數(international index of erectile function)評分。初步結果並不令人意外:兩組在術後 1 個月的膀胱功能皆顯著下降。

  • In the lap TME group, urinary dysfunction gradually improved over a six-month period, which is consistent with previously reported open-surgery TME studies. In other words, both lap and open TME required six months for ISP scores to decrease. However, interestingly, patients who underwent robotic TME showed significantly earlier recovery at a period of less than three months.

    在腹腔鏡 TME 組中,排尿功能在 6 個月期間逐步改善,與先前報告的開腹 TME 研究一致。換言之,腹腔鏡與開腹 TME 皆需要 6 個月讓 ISP 分數下降。然而值得注意的是,接受機器人 TME 的病患恢復顯著更早,時間少於 3 個月。

  • They also analyzed the urinary flow, where the most objective urinary function results were obtained. The robotic TME showed no decrease in mean voiding volume. The robotic TME urinary data analysis revealed superior outcomes compared to laparoscopic TME data, not only an ISP score but also in urinary flow.

    他們也分析了尿流量,以取得最客觀的泌尿功能結果。機器人 TME 的平均排尿量未見下降。機器人 TME 的泌尿數據分析顯示,相較於腹腔鏡 TME,不僅在 ISP 分數上更佳,在尿流量表現上亦更優。

  • With respect to erectile function, the robotic TME group showed earlier recovery as compared to the laparoscopic TME group, six months versus 12 months. They stated that during pelvic dissection, avulsion or direct injury of the nerve plexus can easily happen, which is tied to postoperative sexual and urinary dysfunction. Enhanced 3-D HD magnified views along with 7 degrees of instrument freedom were found to be of high value during delicate dissection.

    就勃起功能而言,機器人 TME 組相較於腹腔鏡 TME 組恢復更早,分別為 6 個月對 12 個月。他們指出,在骨盆剝離過程中,神經叢的撕脫或直接損傷很容易發生,並與術後性功能與泌尿功能障礙相關。增強的 3D HD 放大視野以及器械 7 個自由度,在精細剝離時被認為具有高度價值。

  • In their conclusions, the author stated, and I quote, we conclude that the use of da Vinci's surgical robotic TME system allowed for an earlier recovery in voiding and sexual function because it enabled meticulous dissection and maintenance of adequate counter traction strength as a result of enhanced dexterity. Close quote.

    在其結論中,作者表示,我引用原文,我們的結論是,使用達文西手術機器人 TME 系統可使排尿與性功能更早恢復,因為其提升的靈活性使得能夠進行更精細的剝離,並維持足夠的對抗牽引力。引述完畢。

  • As stated earlier, our GYN franchise remains robust. While most of our previous growth has been US-centric, we are beginning to experience dVH expansion in non-US markets. As was the case in the United States, complex dVH for malignant conditions appears to be the catalyst.

    如先前所述,我們的婦科(GYN)業務版圖仍然穩健。雖然我們過去的大部分成長以美國為主,但我們開始在非美國市場看到 dVH 的擴張。與美國的情況相同,針對惡性疾病的複雜 dVH 似乎是主要催化劑。

  • In this month's edition of Obstetrics and Gynecology, a group made up of both surgeons and epidemiologists from Jewish General Hospital and McGill University in Montreal published their two-year findings on both patient outcomes and economics associated with their robotic GYN cancer program. A total of 303 endometrial cancer patients were involved in the study.

    在本月的《Obstetrics and Gynecology(婦產科學)》期刊中,一個由蒙特婁 Jewish General Hospital 與 McGill University 的外科醫師與流行病學家共同組成的團隊,發表了其機器人婦科癌症計畫在病患結果與經濟性方面的兩年研究結果。共有 303 名子宮內膜癌病患納入研究。

  • Following the initial -- the initiation of their robotics program, 143 consecutive dVH patients were compared to 160 consecutive patients who underwent surgery prior to the robotic program commencement. These 160 patients made up the historical cohort.

    在其機器人計畫啟動之後,將連續 143 名 dVH 病患與在機器人計畫開始前接受手術的連續 160 名病患進行比較。這 160 名病患構成歷史對照組。

  • Within the historical cohort, the rate of minimally invasive surgery performed with traditional laparoscopy was 17%. During the following two post da Vinci years, the MIS rate had grown to 98%.

    在歷史對照組中,以傳統腹腔鏡進行的微創手術比例為 17%。在隨後達文西導入後的兩年中,微創手術(MIS)比例成長至 98%。

  • The patient characteristics were comparable in both areas except areas except for an even higher body mass index in the robotics era. Robotics patients had longer operating times but fewer adverse events, 13% compared to 42%; lower estimated median blood loss, lower by approximately 70%; and shorter median hospital stay, 2.2 days compared with 5.5 days.

    兩個時期的病患特徵大致相當,唯獨在機器人時期的身體質量指數(BMI)更高。機器人手術病患的手術時間較長,但不良事件較少,為 13% 相較於 42%;估計的中位數失血量更低,約降低 70%;且住院中位數天數更短,為 2.2 天,相較於 5.5 天。

  • The overall hospital cost for the robotic group was significantly lower as compared with the historical group -- CAD7644 compared with CAD10,368.

    機器人組的整體住院成本顯著低於歷史組——加幣 7,644 元相較於加幣 10,368 元。

  • The gains with robotic surgery are even more pronounced in a multi-variable analysis where they consider both the full cohorts and matched subcohorts. The reduction in grade 2 or higher complications resulting in far less hospitalization drove significant dVH related hospital savings.

    在多變量分析中,機器人手術帶來的改善更為明顯;該分析同時考量完整隊列與配對子隊列。由於 2 級或以上併發症的降低使住院大幅減少,進而帶動與 dVH 相關的顯著住院成本節省。

  • However, the key factor in evaluating any cancer treatment is oncologic outcome. At present, the two-year post-dVH follow-up indicates a lower recurrence rate as compared with the historical cohort.

    然而,評估任何癌症治療的關鍵因素是腫瘤學結果。目前,dVH 術後兩年的追蹤顯示,其復發率低於歷史對照組。

  • Improving procedure efficacy while reducing hospital cost is a powerful combination, and one that aligns us closely to the needs of our patients, providers and payers.

    在提升手術療效的同時降低住院成本,是一個強而有力的組合,也使我們更貼近病患、醫療提供者與支付方的需求。

  • This concludes my remarks and I'll now turn the time over to Calvin.

    以上是我的發言,接下來把時間交給 Calvin。

  • Calvin Darling - Senior Director of Finance

    Calvin Darling - Senior Director of Finance

  • Thank you, Aleks. I will be providing you with an update to our financial forecast for 2012 including procedures, revenues and other elements of the income statement on a GAAP basis. I will also provide estimates of significant non-cash expenses to provide you with visibility into our expected future cash flows.

    謝謝你,Aleks。我將向各位更新我們對 2012 年的財務預測,包括手術量、營收以及依 GAAP 編製的損益表其他項目。我也會提供重大非現金費用的估計,讓各位能更清楚我們預期的未來現金流。

  • Starting with procedures, during the first quarter we saw continued strength in US gynecology procedures and Europe dVPs. We also saw strong global general surgery growth and positive US early market reactions to our Single-Site cholecystectomy offering.

    先從手術量談起,第一季我們看到美國婦科手術持續強勁,以及歐洲 dVP 的強勢表現。我們也看到全球一般外科的強勁成長,並且在美國市場對我們的 Single-Site 膽囊切除術方案出現正面的早期反應。

  • We are now increasing our 2012 procedure guidance. On our last call we forecast procedures to grow approximately 24% to 26% from a base of approximately 360,000 procedures performed in 2011. We now forecast full year 2012 da Vinci procedure volume to grow approximately 25% to 27% above our 2011 total.

    我們現在上調 2012 年手術量指引。在上次電話會議中,我們預測手術量將在 2011 年約 36 萬例的基礎上成長約 24% 至 26%。我們現在預測 2012 年全年達文西手術量將較 2011 年總量成長約 25% 至 27%。

  • Moving on to revenues, we are also increasing our 2012 revenue guidance. Based upon our higher procedure expectations and revenue contributions from new products, we now expect 2012 revenue to grow between 19% and 21% above total 2011 revenue of $1.76 billion. This is up from 17% to 19% revenue growth forecast on our previous call.

    接著談營收,我們也上調 2012 年營收指引。基於較高的手術量預期以及新產品帶來的營收貢獻,我們現在預期 2012 年營收將較 2011 年總營收 17.6 億美元成長 19% 至 21%。這高於我們在上次電話會議中所預測的 17% 至 19% 營收成長。

  • Now turning to operating income, consistent with our previous forecast we continue to expect operating income to fall within a range of between 39% and 40% of net revenue. We will likely trend toward the lower end of this range as result of lower gross profit percentages realized on recently launched instrument products.

    再來看營業利益,與先前預測一致,我們仍預期營業利益將落在淨營收的 39% 至 40% 區間。我們可能會趨近此區間的下緣,原因是近期推出的器械產品所實現的毛利率較低。

  • Now turning to non-cash expenses. We now expect non-cash stock compensation to fall within a range of between $152 million to $156 million for the year, compared to our previous forecast of $144 million to $150 million with the increase driven by higher option valuations associated with our higher stock price.

    接著談非現金費用。我們目前預期全年非現金股票薪酬將落在 1.52 億至 1.56 億美元區間,相較於先前預測的 1.44 億至 1.50 億美元;上調主要是因股價上升導致選擇權估值提高。

  • As Marshall described earlier, we would expect non-cash stock compensation expense to increase in the second quarter, reflecting the full quarter impact of the February 15 grant and to increase further in the third quarter with the August 15 grant. Amortization of purchased intellectual property, which is mostly recorded as R&D expense, is still expected to fall within a range of between $20 million and $24 million in 2012.

    如 Marshall 先前所述,我們預期第二季非現金股票薪酬費用將增加,反映 2 月 15 日授予的整季影響,並在第三季因 8 月 15 日授予而進一步增加。外購智慧財產權的攤銷(多數列為研發費用)仍預期在 2012 年落在 2,000 萬至 2,400 萬美元區間。

  • We expect other income, which is mainly comprised of interest income, to total between $15 million and $17 million for the year.

    我們預期其他收入(主要由利息收入構成)全年合計將在 1,500 萬至 1,700 萬美元之間。

  • With regard to income tax, our Q1 reported tax rate of 27.2% fell below our guidance range of between 29% and 31%, driven by the release of Section 199 reserves -- deductions for US manufacturing activities. Going forward, we expect our tax rates in quarters 2 through 4 to come in at the higher end of our range at around 31% of pretax income. While we will benefit from the ongoing manufacturing activities deduction, we project this benefit will be more than offset by the non-continuance of the US R&D tax credit and a slight shift in our projected geographic mix of pretax profit towards the US.

    就所得稅而言,我們第一季公布的稅率 27.2% 低於我們指引區間 29% 至 31%,主要是因釋放了第 199 條準備——即美國製造活動扣除。展望未來,我們預期第 2 至第 4 季的稅率將落在區間較高端,約為稅前所得的 31%。雖然我們將持續受惠於製造活動扣除,但我們預估此項利益將被美國研發稅額抵減未延續,以及我們預估稅前利潤地理組合略為向美國移動所抵銷,且抵銷幅度將更大。

  • We expect that our share count for calculating EPS in Q2 2012 will be approximately 41.2 million shares. Our higher forecasted share count is driven by higher equivalent shares assigned to the diluted share calculation based on our higher stock price.

    我們預期 2012 年第二季用於計算每股盈餘(EPS)的股數約為 4,120 萬股。我們較高的預測股數主要是因股價較高,使稀釋後股數計算中所分配的等效股數增加。

  • That concludes our prepared remarks. We will now open the call to your questions.

    以上是我們事先準備的發言。現在我們將開放提問。

  • Operator

    Operator

  • (Operator Instructions) Spencer Nam, ThinkEquity.

    (接線員指示)Spencer Nam,ThinkEquity。

  • Spencer Nam - Analyst

    Spencer Nam - Analyst

  • Thanks for taking my questions. Just a couple of questions here. First of all, you know, you guys mentioned a lot about these new products and these different upgrades having impact on your procedure volume. And I'm curious whether the -- well, whether you guys could tell us how much your increase in procedure volume is driven by the upgrades and just new capability introduction versus -- you are actually well going out and just opening up the new procedure areas that you are currently working on.

    謝謝讓我提問。我這裡只有幾個問題。首先,你們提到很多新產品與不同升級對手術量的影響。我想了解的是——嗯——你們能否說明手術量增加有多少是由升級與新功能導入所驅動,相較之下,有多少是因為你們實際上去開拓目前正在推進的新手術領域所帶來的?

  • Aleks Cukic - VP of Strategic Planning

    Aleks Cukic - VP of Strategic Planning

  • Well, I will answer that the best I can as I understand it. First off, I don't know that we had necessarily indicated that the new products, i.e. Single-Site and/or the Vessel Sealer, are the reason for the additional procedure growth, although they did add and contribute to it. The categories of general surgery, which include colorectal surgery, the categories of thoracic surgery, lobectomy, etc. in addition to the strong GYN growth and international dVP growth were really the reason that drove the added procedure for the quarter.

    我會在我理解的範圍內盡力回答。首先,我不確定我們是否曾明確表示新產品,也就是 Single-Site 和/或 Vessel Sealer,是額外手術成長的原因,雖然它們確實有所增加並帶來貢獻。真正推動本季手術量增加的原因,是一般外科類別(包含大腸直腸外科)、胸腔外科類別(肺葉切除等),再加上強勁的婦科成長與國際 dVP 成長。

  • As far as differentiating between new procedures and/or new products, I don't know that we can do that calculation for you. I think in general there is good procedure strength that's happening across the core business, specifically dVP outside of the United States. dVP in the United States was actually down a little bit, but it was more than made up for in the addition of the other procedures that we talked about.

    至於區分新手術與/或新產品的貢獻,我不確定我們能為你做出那樣的計算。我認為整體而言,核心業務各面向都呈現良好的手術量動能,特別是美國以外的 dVP。美國的 dVP 其實略有下滑,但我們所提到的其他手術增加已足以彌補並且超過。

  • Operator

    Operator

  • Tycho Peterson, JPMorgan.

    Tycho Peterson,JPMorgan。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Hey, maybe I'll comment on that last point. You know, you talked about active surveillance and the dynamic there in the US. Can you just talk about -- I mean are you expecting dVP to remain flat here? And just talk about watchful waiting and how you think about that impacting this.

    嗨,也許我針對剛才最後一點追問一下。你提到在美國的主動監測(active surveillance)以及其動態。你能否談談——我的意思是——你們是否預期 dVP 在這裡會維持持平?另外也請談談觀察等待(watchful waiting),以及你們認為這會如何影響整體情況。

  • Aleks Cukic - VP of Strategic Planning

    Aleks Cukic - VP of Strategic Planning

  • Well, I think in general we have been talking about dVP being flattish for some time in the United States, for probably the last three or four quarters. And it is our expectation that as -- and I think you almost have to back away and look at it as dVP, and look at it in general as prostate cancer. And the treatment of the disease of prostate cancer, and what may happen on a macro level with -- if more people end up going into an active surveillance.

    嗯,我想整體而言,我們一直在談美國的 dVP 在一段時間內大致持平,可能是過去三到四個季度。而我們的預期是,隨著——我想你幾乎必須退一步,把它視為 dVP,並且更廣泛地把它視為前列腺癌。以及前列腺癌這個疾病的治療,還有在宏觀層面上可能會發生的情況——如果更多人最後進入主動監測(active surveillance)。

  • And history will tell you that at some point something as high as 60% of those men -- and it could be as high as two-thirds often wind up in some other therapy, either radiation or surgery, so some of this might be a lead/lag effect. We don't really know how to handicap that. I think there is a lot of information that is out there and I think we will probably move up and down with surgery in general.

    而歷史會告訴你,在某個時間點,這些男性中高達 60%——甚至常常可能高達三分之二——最後會轉向其他治療方式,不論是放射治療或手術,所以其中一部分可能是領先/落後(lead/lag)效應。我們並不真正知道該如何衡量這點。我認為外界有很多資訊,而我想我們整體上在手術方面可能會上下波動。

  • And outside of the United States, again, just to underscore, you're seeing the overall dVP number is growing. And that is really driven by both European strength as well as Asian and Latin American and other markets.

    而在美國以外,再次強調,你會看到整體 dVP 的數字正在成長。而這主要是由歐洲的強勁表現,以及亞洲、拉丁美洲和其他市場所帶動。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Can you quantify what the revenues were from Single-Site stocking orders? We have had a few people ask on that.

    你能量化一下 Single-Site 備貨訂單(stocking orders)帶來的營收是多少嗎?我們有幾個人問到這點。

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Single-Site stocking orders, quantify it?

    Single-Site 備貨訂單,要量化它?

  • Aleks Cukic - VP of Strategic Planning

    Aleks Cukic - VP of Strategic Planning

  • We are not going to quantify it, just tell you that -- like we said in the script, the attach rate for Single-Site was reasonable in the quarter. So we are still in the early stages. It's not -- I think if we gave out numbers now, it really wouldn't be an indication of much.

    我們不會量化它,只能告訴你——就像我們在講稿裡說的,本季度 Single-Site 的搭載率(attach rate)是合理的。所以我們仍在早期階段。這不是——我想如果我們現在給出數字,其實也不太能代表什麼。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Last one on service margins, I think they were at a record this quarter. You know, just talk about the sustainability of the service margins there and what's kind of driving this strength.

    最後一個關於服務毛利率的問題,我想本季度它創下紀錄。你能談談服務毛利率的可持續性,以及是什麼在驅動這股強勢嗎?

  • Aleks Cukic - VP of Strategic Planning

    Aleks Cukic - VP of Strategic Planning

  • Really improvements in product quality, reducing the amount of time that our field engineers have to spend servicing the equipment and leveraging more systems over the existing field service engineer force. It will fluctuate a little bit here and there, but I think that you've seen the margins over the last few quarters at a certain level, and it should continue at that level.

    主要是產品品質的改善,減少我們現場工程師花在設備維修上的時間,並且在既有的現場服務工程師人力下支撐更多系統。它會在這裡那裡有些波動,但我想你已經看到過去幾個季度毛利率維持在某個水準,並且應該會持續在那個水準。

  • Operator

    Operator

  • Ben Andrew, William Blair.

    Ben Andrew,William Blair。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • Good afternoon, Aleks or Gary, maybe a question for you. If you think about the relative benefits of single-incision cholecystectomy versus lap, are you seeing enough kind of evidence of that benefit in the early days that convinces you the procedure trajectory is going to be very strong? Just talk a little bit about the selling process and what you are seeing in the initial rollout, if you would.

    下午好,Aleks 或 Gary,可能問你們一個問題。若你們思考單切口膽囊切除術相對於腹腔鏡(lap)的相對效益,你們在早期是否看到足夠的證據顯示這些效益,讓你們相信該手術的發展軌跡會非常強勁?也請談談銷售流程,以及你們在初期推廣(rollout)中看到的情況。

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • You know, I think on the first part of where the benefits are -- the early anecdotes we are hearing are a combination of benefits on pain and benefits on cosmesis. How these play out over time and what segment of the broader population is interested in those things, hard to forecast right now. So we'll see.

    你知道,我想在第一部分、也就是效益在哪裡——我們目前聽到的早期軼聞(anecdotes)是疼痛方面的效益與外觀美觀(cosmesis)方面的效益的組合。這些效益會如何隨時間發展,以及更廣泛人群中哪一個族群對這些事情有興趣,現在很難預測。所以我們再觀察。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • Gary, are you hearing that that's patient-driven or physician-driven? Because we've heard some comments that a single-site through the umbilicus can actually be more painful in a way than the four ports of a typical lap chole.

    Gary,你聽到的是病人驅動還是醫師驅動?因為我們聽到一些評論說,經由肚臍的單孔(single-site)反而可能比典型腹腔鏡膽囊切除的四個穿刺孔更痛。

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Yes, mostly what we're hearing is a little bit of both. We hear both the surgeon commentary on it as well as some patient commentary on it. But it is early days, and I there'll be conflicting opinions for a while, until there is a large enough procedure base and evidence base for it to sort out. I will let Aleks speak to the selling process.

    是的,我們聽到的大多是兩者都有。我們同時聽到外科醫師的評論,也聽到一些病人的評論。但這還是早期,而且我想在一段時間內會有相互矛盾的看法,直到有足夠大的手術量基礎與證據基礎,才能把它釐清。我讓 Aleks 談談銷售流程。

  • Aleks Cukic - VP of Strategic Planning

    Aleks Cukic - VP of Strategic Planning

  • You know, again, if you look at the market before we entered into it, I think there were a fair amount of physicians and hospitals that were interested in single-incision surgery, as evidenced by the number of surgeons that were trained and some of the early successes that some of the other companies may have had in that area. So, the demand is there in terms -- let's say that the interest level is there.

    你知道,再次,如果你看我們進入之前的市場,我想有相當多的醫師與醫院對單切口手術有興趣,這從受訓外科醫師的人數,以及其他公司在該領域可能取得的一些早期成功就能看出來。所以,就需求而言——我們可以說興趣程度是存在的。

  • And in terms of the sales process I think we are seeing a few things converge at the same time. You're seeing general surgeons who have garden-variety procedures like cholecystectomy. At same time you're seeing colorectal surgeons, who don't necessarily get involved in those types of surgeries, and you're seeing other areas.

    而就銷售流程而言,我想我們看到幾件事同時匯聚。你會看到一般外科醫師有像膽囊切除這類常見(garden-variety)的手術。同時你也會看到大腸直腸外科醫師,他們不一定會參與這類手術,另外也看到其他領域。

  • We don't talk about it because they're not large markets. But if we look at procedures like adrenalectomies and some of the upper GI gastric surgeries, etc. they are all on small ends but nice trajectories.

    我們不太談這些,因為它們不是大型市場。但如果我們看像腎上腺切除術(adrenalectomies)以及一些上消化道的胃部手術等等,它們規模都偏小,但走勢(trajectories)不錯。

  • So there seems to be a lot of global awareness from the general surgeon that is making it let's say easier for our people to get in front of, and then consolidate the messaging of robotics programs to include general surgery. So there really isn't any sort of paint by numbers here that we can say is consistent, other than there is a lot of global awareness in this category right now.

    所以,似乎一般外科醫師在全球範圍內的認知度很高,這讓我們的人更容易接觸到他們,並且把機器人手術計畫的訊息整合進來,納入一般外科。因此,這裡並沒有任何所謂按表操課(paint by numbers)的固定模式可說是一致的,除了目前這個類別在全球的認知度確實很高。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • And maybe two other quick questions. You talked about Europe placements being weak. What is your outlook for the year?

    另外也許再兩個快速問題。你提到歐洲的裝機(placements)偏弱。你對今年的展望是什麼?

  • I know it's probably baked into your guidance, but do you think -- do you assume that it gets better? Or are you baking into it staying relatively tough even though procedure growth was pretty good? And what are you hearing about the magnitude of hospital budgets relative to procedure capability as we go through the year?

    我知道這可能已經反映在你們的指引(guidance)裡,但你認為——你是否假設情況會變好?還是你把它納入為即使手術量成長相當不錯,環境仍會相對艱困?以及你們聽到的醫院預算規模相對於手術能力的情況,在今年進行過程中會如何?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • A couple of questions in there. We think it will remain pressured for some time to come, so we're not forecasting that the pressure comes off capital budgets. As you said, the procedure side has been reasonably healthy to date. How expenditures reflect back into procedures is really hard for us to handicap. I think we're just going to have to wait and see where that goes.

    裡面有幾個問題。我們認為壓力在未來一段時間仍會持續,所以我們並沒有預測資本預算(capital budgets)的壓力會解除。正如你所說,手術端到目前為止相對健康。支出如何回饋到手術量上,對我們來說真的很難評估。我想我們只能等著看後續發展。

  • Ben Andrew - Analyst

    Ben Andrew - Analyst

  • Then finally a quick one for Marshall. You talked about gross margin pressure early on with the rollout of seals and the new products. Is that something we could see resolving over the course of this year, or maybe takes a bit longer to get enough scale there? Thanks.

    最後一個快速問題給 Marshall。你提到在 seals 與新產品推廣初期,毛利率會有壓力。這是否可能在今年內逐步解決,還是可能需要更久才能達到足夠規模?謝謝。

  • Marshall Mohr - CFO

    Marshall Mohr - CFO

  • We're not going to put a timeframe on it. I would just say, like I said in the script, that over time we will -- we are working towards revising our production processes as well as the product itself in driving the cost down.

    我們不會給出時間表。我只能說,就像我在講稿裡說的,隨著時間推進,我們會——我們正致力於修訂我們的生產流程以及產品本身,以推動成本下降。

  • Operator

    Operator

  • David Lewis, Morgan Stanley.

    David Lewis,Morgan Stanley。

  • David Lewis - Analyst

    David Lewis - Analyst

  • Good afternoon, a couple of quick questions. I want to try to maybe, Aleks or Gary, to rectify the revenue per procedure numbers. Obviously stronger than we would have thought, and you talked about general surgery being a contributor to incremental growth.

    下午好,兩個快速問題。我想嘗試——也許 Aleks 或 Gary——釐清每例手術營收(revenue per procedure)的數字。顯然比我們原先想的更強,而你們也談到一般外科是增量成長的貢獻者。

  • So, I'm trying to figure out if general surgery comes on, revenue per procedure should trend down slightly, but in this quarter it trended up. And it did contribute to growth. So could you just give us more granularity on revenue per procedure going up, even though general surgery did contribute to positive growth acceleration?

    所以,我試著理解:如果一般外科上來,每例手術營收應該會略微下滑,但本季度卻上升。而且一般外科確實對成長有貢獻。所以你們能否更細緻地說明,為什麼在一般外科也帶來正向成長加速的同時,每例手術營收仍然上升?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • So when we are selling seal kits or our single-incision product (multiple speakers) Single-Site product, we are -- they are buying it as a kit. And they may not have done any surgeries yet, right?

    所以當我們在銷售 seal 套件或我們的單切口產品(多位發言者)Single-Site 產品時,我們——他們是以套件(kit)的形式購買。而他們可能還沒有做任何手術,對吧?

  • So that is really what is helping increase the revenue per procedure. That as well as Firefly, as well as thoracic kits, so they're buying instruments and accessories in advance of doing the procedure. Now over time, they will be doing the procedures and then that will balance out.

    所以這其實就是在幫助提高每例手術營收的原因。再加上 Firefly,以及胸腔(thoracic)套件,他們是在進行手術之前就先購買器械與配件。當然,隨著時間推進,他們會開始做手術,然後這就會平衡回來。

  • Long-term I think your question is, is the price they are paying for single-incision products less than what we are charging for our normal -- our multiple incision products, and the answer is yes.

    長期來看,我想你的問題是:他們為單切口產品支付的價格是否低於我們對一般——多切口產品的收費?答案是是的。

  • David Lewis - Analyst

    David Lewis - Analyst

  • Okay, so it sounds like even though the ancillary products like Firefly are doing obviously well, you still believe over time this trend is going to annualize down?

    好的,所以聽起來即使像 Firefly 這類輔助產品(ancillary products)表現顯然很好,你們仍然相信隨著時間推進,這個趨勢會在年度化(annualize)後往下?

  • Marshall Mohr - CFO

    Marshall Mohr - CFO

  • Over time, it is hard to exactly predict because the mix of new products and the mix of procedures is hard to forecast precisely. And so, some of them carry it up and some of them push it down, and so you have those two things working in opposition.

    隨著時間推進,很難精準預測,因為新產品的組合以及手術組合都很難精確預測。因此,有些因素會把它拉高,有些因素會把它壓低,所以你會看到這兩股力量相互對抗。

  • David Lewis - Analyst

    David Lewis - Analyst

  • And I know it's early, but is it safe to assume that in the earliest days of the initial general surgery traction that the majority of the success has been in chole versus other procedures?

    我知道現在還早,但是否可以合理假設,在一般外科初期導入、開始有起色的最早階段,多數的成功主要來自膽囊切除(chole),而不是其他手術?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • You are seeing really two different -- general surgery for us is a tale of two different activities. We have strength in colorectal, which is typically cancer procedures that would otherwise have been done open, and so that tends to be one set. There is a larger volume there.

    你其實看到的是兩種不同的情況——對我們而言,一般外科可說是兩種不同活動的故事。我們在大腸直腸手術方面很強,這通常是癌症手術,原本可能會以開腹方式進行,因此這是一個面向。而且那邊的量更大。

  • And then we have Single-Site, which is right now approved for cholecystectomy. So you are seeing those two things kind of as a barbell.

    然後我們還有單孔(Single-Site),目前核准用於膽囊切除術。所以你看到這兩件事有點像槓鈴兩端。

  • As a total number of procedures, I think you're getting more from colorectal in terms of growth than you have in chole so far.

    以手術總量來看,我認為到目前為止,大腸直腸在成長上的貢獻比膽囊切除更大。

  • David Lewis - Analyst

    David Lewis - Analyst

  • Okay, very helpful. One last quick one and I will jump back in queue. Just in terms of an O-US market dynamic question, if you think about your key markets, maybe Japan is less relevant right now. But in terms of Germany, France, Italy, in those key markets is prostatectomy still your single biggest growth contributor? So, not necessarily absolute, but on a growth perspective, is prostatectomy still the biggest driver in those three markets?

    好的,很有幫助。最後再快速問一個我就回到隊列。就美國以外(O-US)市場的動態來問,如果看你們的關鍵市場,日本現在可能沒那麼相關。但就德國、法國、義大利這些關鍵市場而言,前列腺切除術仍然是你們單一最大的成長貢獻者嗎?也就是說,不一定是絕對量,而是從成長角度看,在這三個市場前列腺切除術仍是最大的驅動力嗎?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • The answer is mostly yes, although we are beginning -- you can see high growth off small bases in a couple of other procedures. So, off of a substantial base, the dVP is the highest grower.

    答案大致上是的,雖然我們也開始看到——在其他幾種手術上,基期很小但成長很快。所以若以相當大的基期來看,dVP 的成長仍是最高的。

  • We are beginning to see hysterectomy for cancer conditions starting to come up. And there is some interest in general surgery in Italy, and that is starting to come up on a lower basis.

    我們開始看到因癌症適應症的子宮切除術逐步上來。另外在義大利,一般外科也有一些興趣,這部分也正從較小的基期開始上升。

  • Operator

    Operator

  • (Operator Instructions) Lennox Ketner, BofA Merrill Lynch.

    (接線員指示)Lennox Ketner,BofA Merrill Lynch。

  • Lennox Ketner - Analyst

    Lennox Ketner - Analyst

  • Hi, thanks so much for taking the question. Just to go back to the Single-Site product, our checks suggest you were in probably 20 to 30 hospitals this quarter. I'm just wondering if you're willing to comment on whether that is the right ballpark. And also just wondering, are you still in the -- at a point where you're hand-selecting the sites so that you can work with the early adopters? Or is that product available for broad distribution now?

    嗨,謝謝讓我提問。回到單孔(Single-Site)產品,我們的查核顯示你們本季可能在約 20 到 30 家醫院。我想請問你們是否願意評論這是否大致正確。另外也想問,你們是否仍處於——會手動挑選據點、以便與早期採用者合作的階段?還是這個產品現在已可廣泛供貨?

  • Aleks Cukic - VP of Strategic Planning

    Aleks Cukic - VP of Strategic Planning

  • First, with respect to the number of centers, we really aren't a position to disclose what those numbers are and will probably pass on trying to answer that question. But I would say that during the course of the quarter we have seen a lot of interest both in centers that have purchased and have begun doing cases, as well as the centers who are in the process of being trained.

    首先,關於中心數量,我們目前不便披露這些數字,因此可能先不回答這個問題。但我會說,在本季期間,我們看到很大的興趣,包含已購買並開始做病例的中心,以及正在受訓流程中的中心。

  • So, comparing and contrasting Single-Site versus the Vessel Sealer, Single-Site from a market development standpoint is much further along than Vessel Sealer, which was a product that we started to phase into, roll out in the later half of the first quarter. So you should think of those two differently. Think of Single-Site being further along and think of Single-Site is a product now that customers can get their hands on.

    因此,若對比單孔(Single-Site)與血管封合器(Vessel Sealer),從市場開發的角度來看,單孔的進展遠比血管封合器更往前;血管封合器是我們在第一季後半段才開始逐步導入、推出的產品。所以你應該用不同方式看待這兩者。把單孔視為進展更成熟,並且把單孔視為客戶現在已經可以實際取得並使用的產品。

  • Lennox Ketner - Analyst

    Lennox Ketner - Analyst

  • Okay, and then you mentioned that it's cleared for broader indications in Europe. Is it cleared for additional specific indications in Europe, or does it -- are you clear to use it in anything in Europe?

    好的,另外你提到在歐洲已核准用於更廣泛的適應症。那在歐洲是核准了額外的特定適應症,還是——在歐洲你們已核准可用於任何手術?

  • Marshall Mohr - CFO

    Marshall Mohr - CFO

  • It's cleared in most things in the abdomen. It's not cleared in all parts of the body.

    它在腹部的大多數手術都已核准,但並非身體所有部位都核准。

  • Lennox Ketner - Analyst

    Lennox Ketner - Analyst

  • Okay. And then lastly on Japan, sorry if I missed that. But I was wondering if you said how many systems were sold into Japan, and then also if you could just talk about bit about what the process is for getting additional procedures approved in Japan. And I know you were kind of -- last quarter at least still debating which procedures to pursue there next, but if you could maybe just talk a little bit about the process there and whether you have made any decisions?

    好的。最後關於日本,抱歉如果我漏聽了。我想問你們是否提到本季賣到日本多少套系統?另外也請談談在日本取得更多手術項目核准的流程。我知道你們——至少上季——還在討論下一步要在那裡推哪些手術,但如果可以的話,請稍微談一下那邊的流程,以及你們是否已做出任何決定?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Sure, so the first question was how many went into Japan this quarter. It was seven. With regard to what happens next in terms of reimbursements, first, we're happy to have the first one in there.

    當然。第一個問題是本季進入日本多少套,是 7 套。至於接下來在給付(reimbursement)方面會發生什麼,首先,我們很高興第一個已經進去了。

  • Going forward, the process changes a little bit. And the surgical societies are then the groups that lead the pursuit of a reimbursement beyond the first one, and so we will be in support of those societies as they look to see where they want to go.

    往後流程會有些不同。外科醫學會將成為推動第一項之外後續給付的主導團體,因此當這些學會評估下一步要往哪裡走時,我們會提供支持。

  • It's a little bit early to figure out which one will be the next one in queue, but those societies are interested and they're starting to talk to us about it. As we know more, then we'll report more in future quarters.

    目前要判斷下一個排隊的會是哪一項還有點早,但這些學會很有興趣,也開始就此與我們討論。等我們掌握更多資訊後,會在未來幾季再做更多說明。

  • Lennox Ketner - Analyst

    Lennox Ketner - Analyst

  • Great, thanks so much. Congratulations.

    太好了,非常感謝。恭喜。

  • Operator

    Operator

  • Rick Wise, Leerink Swann.

    Rick Wise,Leerink Swann。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Good afternoon everybody. Let me go back to the Europe issues again. Did I hear you correctly that part of the issues that you cited disappointing were the external factors, but some of them, if I understood you, were organizational? And you said you are taking steps to improve. Can you expand on that and give us a little more color on what you are doing and maybe how much of what was disappointing was related to internal versus external issues?

    各位下午好。我再回到歐洲的議題。我是否聽對了:你們提到令人失望的部分原因是外部因素,但如果我理解沒錯,其中有些是組織面的?而你們說正在採取措施改善。你們能否展開說明、提供更多細節,談談你們在做什麼,以及令人失望的部分有多少與內部因素相關、多少與外部因素相關?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Yes, it's hard to quantify the differences. You did hear us right. I think there's some things we can do to strengthen our capabilities in Europe, and they tend to be around things like economics report, health technology assessments, marketing, those kinds of market access and structural issues more than they are sales process type. So we're working on those things, I think we're making some investments in them.

    是的,這很難量化差異。你確實聽得沒錯。我認為我們可以做一些事來強化我們在歐洲的能力,主要圍繞在像是經濟性報告、健康科技評估(HTA)、行銷等這類市場准入與結構性議題,而不是銷售流程類型的問題。所以我們正在處理這些事情,我想我們也正在對此進行一些投資。

  • How to distinguish how much is one and how much is the other is very tough to do. We don't know exactly how to do that.

    要區分到底各占多少比例非常困難。我們也不知道要如何精確地做這種拆分。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Was sort of a minor factor really this quarter or this is something that really could make a significant difference as you address it in the second half, let's say?

    這在本季其實只是相對次要的因素,還是說這是你們在下半年著手改善後,可能帶來顯著差異的事情?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • It's clear there are economic pressures in Europe having nothing to do with us, and so I think -- and those things are going to exist. How quickly we can add some capabilities and make some changes, that's going to be hard-pressed to forecast. They are directionally correct and we will make those investments and progress.

    很明顯歐洲存在與我們無關的經濟壓力,所以我認為——而且那些因素會持續存在。我們能多快補強一些能力並做出一些改變,將很難預測。但方向是正確的,我們會進行那些投資並推動進展。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Two other quick ones. You highlighted the transference of the da Vinci S license from J&J to you. Is there any economic impact that we should think about, or ability to sell or freedom of action that that helps with that we should understand?

    另外兩個快速問題。你們提到 da Vinci S 授權從 J&J 轉移到你們名下。這是否有任何我們需要考量的經濟影響,或是對銷售能力或行動自由(freedom of action)有任何幫助,是我們應該理解的?

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • There is not nothing material in terms of the commercial aspect of revenue or cost. What it does allow us to do is move on our timelines a little more quickly with regard to approvals of future products, and the ability to be more responsive to the marketplace. And so that is really the excitement of it for us.

    在營收或成本等商業面向上,沒有任何重大的實質影響。它讓我們能做的是:在未來產品核准的時程上可以更快一些,並且能更即時回應市場。因此,這才是我們感到興奮的地方。

  • Rick Wise - Analyst

    Rick Wise - Analyst

  • Last quick one, you mentioned no stock buybacks in either the fourth quarter or the first quarter. I don't know how to ask about this, and rudely, why not? What are the factors that might drive that process? Thanks.

    最後一個快速問題,你提到第四季與第一季都沒有進行庫藏股回購。我不知道該怎麼問,而且可能有點唐突,為什麼不回購?有哪些因素會驅動你們做出回購的決策?謝謝。

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Warren Buffett wrote in his shareholder letter something on this point that I thought was great, and I will just quote it for you. He says he looks for two conditions to be satisfied to buy back stock. And I will quote him, quote -- first, the company has ample funds to take care of the operational and liquidity needs of its business. Second, its stock is selling at a material discount to the company's intrinsic business value, conservatively calculated, unquote. I think he says it right. I think we are happy to emulate his behavior here and that is how we think about it.

    華倫·巴菲特在致股東信中針對這點寫了一段我覺得很棒的內容,我直接引用給你。他說他回購股票會看兩個條件是否滿足。我引用他原文——第一,公司有充足資金以滿足其業務的營運與流動性需求。第二,其股票以相對於公司內在商業價值(以保守方式計算)的重大折價在交易——引用結束。我認為他說得很到位。我們也很樂意在這裡效法他的作法,這就是我們思考回購的方式。

  • Operator

    Operator

  • And our last and final question comes from Michael Matson, Mizuho Securities.

    我們最後一題來自 Michael Matson,Mizuho Securities。

  • Michael Matson - Analyst

    Michael Matson - Analyst

  • Yes, just taking sort of -- standing back taking a bigger picture view of things, I guess first of all, you have got -- hysterectomy is obviously doing extremely well in the US. But by my math I think you are kind of getting upwards of in the 50% range now in terms of penetration. And I guess in another year or two, that is going to start to peak, I guess.

    是的,我想稍微——退一步用更宏觀的角度來看。首先,你們的子宮切除術在美國顯然表現非常好。但按我的計算,你們在滲透率方面現在大概已經接近 50% 以上了。我想再過一兩年,這應該就會開始見頂,我想。

  • And so, where -- what do you really see beyond that to pick up the slack, if that is really starting to slow down as what we've seen with prostatectomy? Do you think it's really going to be Single-Site? Do you think it's the just the combination of the multitude of these other smaller procedures? Do you think it's general surgery? Just be interested in getting your thoughts there.

    那麼,除了那之外——如果如同我們在前列腺切除術所看到的那樣,真的開始放緩,你認為還有什麼能夠彌補缺口?你覺得真的會是單孔(Single-Site)嗎?你覺得只是這些其他眾多較小手術的組合嗎?你覺得是一般外科嗎?只是想聽聽你的想法。

  • Aleks Cukic - VP of Strategic Planning

    Aleks Cukic - VP of Strategic Planning

  • Think about it this way, Michael. You have got -- if we went back in time in 2005 or so, where that question was asked as to what are you going to do when US prostatectomy reaches its height, we weren't talking about hysterectomy. We weren't talking about US hysterectomy, let alone international hysterectomy.

    Michael,你可以這樣想。如果我們回到2005年前後,當時有人問:當美國的前列腺切除術達到高峰時你們要做什麼——那時我們還沒在談子宮切除術。我們甚至沒在談美國的子宮切除術,更不用說國際市場的子宮切除術。

  • We weren't talking about lobectomy. We weren't talking about any of these procedures. Now -- or Single-Site and general surgery in general.

    我們也沒在談肺葉切除術。我們沒在談任何這些手術。更不用說單孔(Single-Site)以及一般外科整體。

  • So, when I sort of fast-forward the tape to where we are today, so recognize that dVP US has been flat for some time, you know, let's call it a year. And yet we are growing at a pretty significant rate. Why? Because there are other ways to sort of slice and look at it internationally. dVP internationally is growing at a very quick rate and it is a larger market than the US dVP market potentially.

    所以,當我把時間快轉到今天,請注意:dVP 在美國已經持平一段時間了,你知道的,就算一年吧。但我們仍以相當顯著的速度成長。為什麼?因為還有其他方式可以切分並從國際角度來看。dVP 在國際市場成長非常快,而且其市場規模可能比美國 dVP 市場更大。

  • Now when you look at dVH, you are talking about the US dVH market, which we segmented down to a certain number, but it doesn't include non-US geographies. We are continuing to add procedures, and when you add general surgery, whether it be through single incision or other multiple incision procedures, and you continue to add thoracic, etc. there is plenty for us to do. We don't feel as if we are running out of steam or running out of procedures. But by all means, we feel completely the opposite.

    再看 dVH,你談的是美國的 dVH 市場,我們把它細分到某個數字,但那不包含美國以外的地區。我們持續增加手術項目;當你把一般外科納入,不論是透過單切口或其他多切口手術,並且持續加入胸腔外科等,對我們而言還有很多事可做。我們不覺得自己正在失去動能或手術項目快用盡;恰恰相反,我們的感受完全相反。

  • So at this stage it is -- there is plenty on their plate and we think that over time we will be adding more things to our plate.

    所以在這個階段——他們手上的事情很多,而我們也認為隨著時間推進,我們會把更多事情加到我們的盤子裡。

  • Michael Matson - Analyst

    Michael Matson - Analyst

  • Okay. And just as sort of a follow on to that, just wondering what your thoughts are in terms of hysterectomy in Europe and outside the US. I mean, you kind of commented on it a little bit earlier in the Q&A. But is there any reason to believe that it might not sort of follow what happened in the US?

    好的。作為延伸追問,我想了解你對歐洲以及美國以外地區子宮切除術的看法。我的意思是,你在先前的問答中稍微提到了一點。但是否有任何理由相信,它可能不會像美國那樣發展?

  • I mean I realize these procedures probably aren't' as common, at least on a per capita basis outside the US. But is there any reason to believe, at least for the proportion that are done, that we wouldn't see similar adoption curves with time?

    我知道這些手術在美國以外,至少以人均來看,可能沒那麼常見。但就已經進行的比例而言,有沒有任何理由相信,隨著時間推移,我們不會看到類似的採用曲線?

  • Aleks Cukic - VP of Strategic Planning

    Aleks Cukic - VP of Strategic Planning

  • You know, if you look at it from a couple perspectives, one is that dVH is done for multitude of reasons. It could be endometrial or cervical cancer, ovarian cancer. You move into the benign side and you've got fibroids, multiple fibroids, large fibroids, endometriosis, a combination of all the above and abnormal uterine bleeding, etc.

    你知道,如果從幾個角度來看,其中之一是 dVH 會因為多種原因而進行。可能是子宮內膜癌或子宮頸癌、卵巢癌。再到良性方面,則有子宮肌瘤——多發性肌瘤、大型肌瘤——子宮內膜異位症,上述各種情況的組合,以及異常子宮出血等等。

  • So when you try to draw connections between women's healthcare is performed in the United States or delivered in the United States, and try to compare it to other markets, it's a little bit different, whereas prostatectomy is done for the same reason. They're all done for cancer.

    所以當你試圖把美國女性醫療照護的執行方式或提供方式,與其他市場做比較並建立連結時,會有些不同;而前列腺切除術則是因為同一個原因而做——都是因為癌症。

  • Cancer tends to have consistency in a lot of countries, US and O-US. So, what are thoughts are at this stage is that, not unlike the United States, we would expect the dVH for malignant conditions to probably be the beachhead, if you will, into most of these countries. And what happens after that, we will have to wait and see.

    癌症在許多國家(美國與美國以外)往往具有一致性。因此,我們目前的看法是:與美國類似,我們預期針對惡性病灶的 dVH 很可能會成為進入多數國家的「灘頭堡」(beachhead)。至於之後會如何發展,我們還得再觀察。

  • But thus far, the strength that we've seen is consistent with that explanation. So, overall, I think you can just take away that women's healthcare in general, especially for benign conditions, is different in a lot of countries than it is in the United States.

    但到目前為止,我們看到的強勁表現與這個解釋一致。總體而言,我想你可以得到的結論是:女性醫療照護整體而言,尤其在良性病灶方面,在許多國家與美國的情況不同。

  • Michael Matson - Analyst

    Michael Matson - Analyst

  • All right. That's all I had. Thank you.

    好。我就這些。謝謝。

  • Gary Guthart - President and CEO

    Gary Guthart - President and CEO

  • Thank you. That was our last question. As we have said previously, while we focus on financial metrics such as revenues, profits and cash flow during these conference calls, our organizational focus remains on increasing patient value by improving surgical outcomes and reducing surgical trauma.

    謝謝。那是我們最後一個問題。如同我們先前所說,雖然我們在這些電話會議中聚焦於營收、獲利與現金流等財務指標,但我們組織的重點仍是透過改善手術結果並降低手術創傷,來提升病患價值。

  • I hope the following experience from Kimberley in Florida gives you some sense of what this means in the lives of our patients. Quote, I was diagnosed with vaginal prolapse in November of 2011. I had a hysterectomy two years prior in November of 2009. This is an unfortunate condition caused by several factors such as heredity, number of children -- I have four -- and a previous hysterectomy.

    我希望以下來自佛羅里達州 Kimberley 的經驗,能讓各位感受到這對病患生活的意義。引述:我在2011年11月被診斷為陰道脫垂。我在兩年前、也就是2009年11月做過子宮切除術。這是一種不幸的狀況,由多種因素造成,例如遺傳、孩子數量——我有四個——以及先前的子宮切除術。

  • My gynecologist referred me to Dr. Coyle for the da Vinci procedure due to its minimally invasive nature, and most of all, its highest success rate. I researched the procedure, met with Dr. Coyle, discussed it with my family, prayed, and decided to schedule the surgery. After years of back pain and discomfort, I was looking forward to some relief.

    我的婦產科醫師因為達文西手術的微創特性,最重要的是其最高的成功率,把我轉介給 Coyle 醫師。我研究了這項手術,與 Coyle 醫師會面,和家人討論、祈禱,並決定安排手術。多年來的背痛與不適,讓我很期待能獲得一些緩解。

  • Never did I expect to feel as good as I do today just four weeks post-surgery. The first couple of days after the surgery were the hardest, and that was it. After that, the most difficult thing was adhering to the post-surgery instructions of what I couldn't do because I felt so good.

    我從沒想過在術後僅四週的今天,我會感覺這麼好。手術後的前幾天最難熬,也就那樣了。之後,最困難的反而是遵守術後指示、克制自己不要做某些事,因為我感覺實在太好了。

  • I never realized how much the nagging pain I lived with prior to the procedure was affecting my life. Now I feel so renewed, refreshed and easily 10 years younger. I would like to say thank you to Dr. Coyle and his team for their continued pursuit of technological advances in the medical field, their commitment to medical excellence and true compassion for their patients' well-being.

    我從未意識到,在手術前我一直忍受的那種惱人的疼痛,對我的生活影響有多大。現在我感覺煥然一新、神清氣爽,彷彿年輕了10歲。我想對 Coyle 醫師及其團隊說聲謝謝,感謝他們持續追求醫療領域的技術進步、對醫療卓越的承諾,以及對病患福祉真誠的同理心。

  • I would also like to thank those who created the da Vinci robot for their commitment to these types of advancements in medical technology that makes such a positive difference in people's lives. If you are considering this procedure, do yourself a favor and say yes. The outcome is truly worth passing on to others. End quote.

    我也想感謝那些創造達文西機器人的人,因為他們致力於推動這類醫療科技的進步,為人們的生活帶來如此正面的改變。如果你正在考慮這項手術,幫自己一個忙,答應它吧。結果真的值得分享給其他人。引述結束。

  • Patients like Kimberly are the strongest advocates for da Vinci surgery and form the very foundation of our operating performance. We have built our Company to take surgery beyond the limits of the human hand, and I assure you that we remain committed to driving the vital few things truly make a difference.

    像 Kimberly 這樣的病患,是達文西手術最有力的倡議者,也是我們營運表現最根本的基礎。我們打造公司,是為了讓手術超越人手的極限;我向各位保證,我們仍致力於推動那少數幾件真正能帶來改變的關鍵事項。

  • This concludes today's call. We thank you for your participation and support on this extraordinary journey to improve surgery, and we look forward to talking to you again in three months.

    今天的電話會議到此結束。感謝各位在這段改善手術的非凡旅程中的參與與支持,我們期待三個月後再與各位交流。

  • Operator

    Operator

  • Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and using AT&T's Executive Teleconference Service. You may now disconnect.

    各位女士、先生,今天的會議到此結束。感謝各位的參與並使用 AT&T 的高階主管電話會議服務。您現在可以掛線。